TNFRSF17 and Miyoshi myopathy: At present, the CAR T-cell products approved for clinical use in MM are idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), both of which target the B-cell maturation antigen (BCMA) on the surface of PCs [11,12].